Other Events ·
Adicet Bio announced the completion of the last patient visit for the planned Phase 1 safety and efficacy analysis of…
ACETAdicet Bio, Inc.
Adicet Bio announced the completion of the last patient visit for the planned Phase 1 safety and efficacy analysis of prula-cel in patients with systemic lupus erythematosus (SLE) with or without lupus nephritis. Topline data from this analysis, which includes 22 SLE patients, is expected to be reported in September 2026. The company also disclosed FDA clearance of its Investigational New Drug application for ADI-212, a gene-edited cell therapy candidate for metastatic castration-resistant prostate cancer (mCRPC), with Phase 1 enrollment planned for the fourth quarter of 2026. Additionally, Adicet is advancing its in vivo CAR-T platform, expecting the first candidate to enter clinical development in the second half of 2027. Adicet Bio operates as a clinical-stage biotechnology company developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies for autoimmune diseases and cancers.